| CBOE |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$3.63 vs. cons $3.48 |
MEDIUM |
| CBOE |
Report |
Net revenue |
BEAT |
pred ~$738 million vs. cons $719 million |
MEDIUM |
| CBOE |
Report |
Adjusted operating expenses |
BEAT |
pred ~$203 million vs. cons $208 million |
MEDIUM |
| CBOE |
Guide |
Organic total net-revenue growth |
BETTER |
guide ~16%-18% vs. cons 15% (FY2026) |
MEDIUM |
| CBOE |
Guide |
Adjusted operating expenses |
LOWER |
guide ~$830-$845 million vs. cons $845.5 million (FY2026) |
MEDIUM |
| CBOE |
Guide |
Data Vantage organic net-revenue growth |
UNCHANGED |
guide ~11%-13% vs. cons 12% (FY2026) |
MEDIUM |
| CBOE |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.8% |
— |
MEDIUM |
| CBOE |
Return |
5-day cumulative residual |
+5.2% (FOLLOW-THROUGH) |
A revenue-led beat plus higher FY2026 growth guidance should lift FY2026-FY2027 EPS estimates by roughly 2%-4% versus pre-report estimates; visible restructuring savings reduce the risk that the initial gain fades. |
MEDIUM |